SOLID TUMORS

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This early-phase trial is testing a new drug called DCSZ11 alongside standard chemotherapy or immunotherapy in 9 people with advanced or metastatic solid tumors, including head and neck cancer. The main goal is to see if the combination is safe and whether it can shrink tumors. B…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug called SOA101, a special antibody that grabs onto cancer cells and helps the immune system attack them. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other good treatment options. The trial will first fi…

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatm…

This early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day c…

This early-phase study tests a new drug called BL-M24D1 in 33 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and get a first look at whether the drug shrinks tumors. Participants receive the d…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This early-stage trial tests a new drug called QTX3034, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 250 participants will take …

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This early-stage trial is testing an experimental drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer medicines. The main go…

This early-stage trial is testing a new oral drug called PEP08 in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find a safe dose and see if the drug shows any signs of shrinking tumors, either alone or with other treatments. Abo…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study follows up to 3,500 cancer patients who are already taking or have taken pembrolizumab (Keytruda) in earlier trials. The goal is to check how safe and effective the drug is over a longer period. Participants may continue treatment or just be monitored, depending on the…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruite…

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them fro…

This early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tu…

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney injury caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for three days around their chemo infusion. Research…

This phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to increase white blood cell counts, lowering the risk of severe infections. Researchers are checking how safe the drug is and how the body proc…

This study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at leas…

This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors (including stomach, esophageal, and colorectal cancers) whose previous treatments have stopped working. Participants receive JR8603 by IV infusion three time…

This early-stage study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the …

This early-phase study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific FGF/FGFR gene changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for early signs…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have worsened after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is the first time this drug is being tested in human…

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in 100 adults with solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. Participants must be 18-75, in good general health, and have a life e…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This early-stage study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors. The goal is to see if it is safe and tolerable when taken alone or with other cancer drugs. About 362 participants will join, and the study is currently …

This early-stage study tests a new drug called BL-ARC002 in 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests a new drug called ABL103 combined with pembrolizumab (with or without a chemotherapy called taxane) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control t…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase study tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals …

This early-stage trial tests a new drug, VLPONC-01, injected directly into tumors in people with head and neck cancer. The study aims to see if it is safe and whether combining it with an immunotherapy drug (pembrolizumab) can shrink tumors better than the immunotherapy alone. Ab…

This early-stage study tests an experimental drug called GSK5733584 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also see if the drug can shrink tumors. …

This study tests an experimental drug called ICP-723 in adults and teenagers with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 310 participants will take part i…

This study tests two drugs, envafolimab and lenvatinib, together in people with advanced solid tumors (lung, kidney, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the combination can shrink tumors better than current options. About 17…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to specific proteins on cancer cells and deliver a chemotherapy-like payload directly to them. The main goal…

This study tests an experimental drug, ZL-1310, in about 112 adults with advanced neuroendocrine carcinomas that have worsened after standard chemotherapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants will receive the drug and be mo…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This early-stage trial tests a new cell treatment called GK01, given alone or with chemotherapy, for people with advanced solid tumors like pancreatic or stomach cancer. The main goal is to check safety and how the body handles the treatment. About 15 participants will be enrolle…

This early-phase study tests a new drug called INCB161734, alone or with other cancer treatments, in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety and find the right dose. About 710 adults whose cancer has worsened a…

This study tests a new drug called S-531011, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The goal is to find safe doses and see if the drug can shrink tumors or slow their growth. About 282 adults with…

This early-stage study tests a new drug, XB371, in about 150 people with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the best dose. Participants must be in fairly good health and have a life expectancy of at least 12 w…

This study tests an experimental drug called SHR-4610 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control tumors. About 258 participants will take part across two phases.

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of …

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be 18-75 and …

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This early-stage study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow cancer growth. Participants…

This study tests a drug called ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About 70 children will take…

This study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…

This early-stage study is testing a new radioactive dye called RT01-89Zr that attaches to a protein found on many solid tumor cells. The goal is to see if it can safely and clearly show tumors on PET/CT scans. About 10 adults with advanced solid tumors will receive the dye and be…

This study tests a drug called romiplostim N01 to help children and young adults (ages 6-24) with cancer recover from dangerously low platelet counts caused by chemotherapy. About 50 participants will receive weekly injections, and researchers will monitor how many achieve safe p…

This study is collecting medical data and biological samples from 15,000 people receiving radiation therapy for solid tumors or blood cancers. Researchers aim to understand how radiation affects quality of life, side effects, and survival. The goal is to learn from real-world out…

This study looks at the genes in cancer tumors to find mutations that might be important for how the cancer grows. Researchers will use leftover tissue from surgeries or biopsies, along with a blood or saliva sample, to compare cancer genes to normal genes. The goal is to underst…

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study is collecting information from 1,000 people with solid tumors who receive chemotherapy through a special catheter called RenovoCath, which delivers drugs directly to the tumor site. Researchers are tracking safety, side effects, and survival over time. The goal is to l…

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will re…